Life Sciences and Healthcare
Developing solutions that will enable you to stay competitive in this rapidly evolving market with the support of our in-depth knowledge.
Transforming life sciences and healthcare innovation into sustainable growth and better outcomes.
Across biotechnology, pharmaceuticals, medical devices and healthcare, our practical audit, tax, advisory and transaction expertise helps you commercialise new products, adopt digital technologies, improve efficiency and enter new markets. Manage costs, respond to regulatory change and scale with confidence.
In the wake of the recent acceleration of this fast-changing environment, our team provides specialised services to help healthcare and life sciences organisations in a transformative, fast-changing environment.
Our experience supporting mergers, acquisitions and public listings gives ambitious organisations the insight and assurance needed to fund growth and complete complex transactions. The AIM Advisers Rankings Guide ranks us second in the UK by number of AIM-listed healthcare audit clients.
Fund and accelerate growth
Secure the finance, investment and incentives needed to advance innovation, commercialise new products and pursue strategic opportunities.
Fund and accelerate growth
Scale with confidence
Strengthen financial operations, improve efficiency and access flexible outsourced support, freeing your team to focus on innovation and expansion.
Scale with confidence
Risk/regulatory complexity
Meet compliance and financial reporting requirements, strengthen governance and respond confidently to an evolving regulatory environment.
Risk/regulatory complexity
Investment, transactions or exit
Build investor confidence, assess opportunities and navigate mergers, acquisitions, public listings or exit with specialist transaction support.
Investment, transactions or exit
Specialist expertise across Life Sciences and Healthcare
Biotechnology
From funding to exit, we help biotechnology businesses strengthen finances, claim innovation reliefs and meet investor expectations.
Drug discovery and Development
Practical support with funding, cashflow and reporting prepares drug developers for investment, licensing and growth.
Pharmaceutical Services
Clearer financial insight helps pharmaceutical service providers expand, attract investment or prepare for sale.
From funding to exit, we help biotechnology businesses strengthen finances, claim innovation reliefs and meet investor expectations.
Practical support with funding, cashflow and reporting prepares drug developers for investment, licensing and growth.
Clearer financial insight helps pharmaceutical service providers expand, attract investment or prepare for sale.
Medical devices
Specialist support helps medical device businesses fund innovation, manage tax and reporting, and enter new markets.
Health and Social Care
Stronger governance and sustainable planning help health and social care providers navigate funding and workforce pressures.
Health Technology
The right financial support enables health technology businesses to fund innovation, strengthen controls and scale confidently.
Specialist support helps medical device businesses fund innovation, manage tax and reporting, and enter new markets.
Stronger governance and sustainable planning help health and social care providers navigate funding and workforce pressures.
The right financial support enables health technology businesses to fund innovation, strengthen controls and scale confidently.
Our latest Life Science and Healthcare deals
M&A insight series
What are the key stages of the buy-side M&A lifecycle?
Whether you're acquiring your first business or refining an established acquisition strategy, understanding each stage of the M&A lifecycle is critical to deal success. This six-part series takes buyers through every phase of the acquisition journey, from identifying potential targets and conducting due diligence to valuation, deal completion and post-acquisition integration.
Completion, SPA protections and integration
Learn how completion planning, SPA protections and post-deal integration help safeguard value and support a successful acquisition outcome.
Tax due diligence, risk assessment and value protection
Identify tax exposures, evaluate transaction risks and secure the appropriate protections needed to preserve value throughout the deal process.
Financial due diligence and risk assessment
Understand how financial due diligence validates earnings, assesses risk and provides the insights needed to support pricing and negotiations.
Valuation, structuring and Heads of Terms
Turn acquisition opportunities into viable transactions through robust valuation, effective deal structuring and carefully crafted heads of terms.
Target identification and early-stage evaluation
Identify and assess acquisition targets with confidence. Learn how to refine search criteria, evaluate strategic fit and spot potential risks early.
Understanding the buy-side M&A lifecycle
Discover the key stages of a disciplined acquisition process and learn how strategic buyers move from opportunity identification to successful deal completion.
Events
Autumn Budget 2026: Expert analysis and insights
Live event - 28 October 2026
Autumn Budget 2026: Live watch-along and expert discussion
Hear the Autumn Budget as it happens and get beyond the headlines with expert analysis from Crowe UK specialists.
Webinar - 30 October 2026
Autumn Budget 2026
Join our specialist panel session, providing an in-depth review of what the Autumn Budget announcements mean for you and your organisation.
How will the 2026 capital allowance reforms affect leasing, second-hand assets and sustainable investment decisions?
Have organisations consciously determined their disclosure risk appetite under pressure to be transparent about sustainability?
The promotions of Ben Carter and Charlie Copp reinforce the firm’s strategic focus on high growth service lines and key sector specialisms.
How will the 2026 capital allowance reforms affect leasing, second-hand assets and sustainable investment decisions?
Have organisations consciously determined their disclosure risk appetite under pressure to be transparent about sustainability?
The promotions of Ben Carter and Charlie Copp reinforce the firm’s strategic focus on high growth service lines and key sector specialisms.
Contact us
